140 related articles for article (PubMed ID: 15071260)
1. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Card Electrophysiol Rev; 2003 Dec; 7(4):382-6. PubMed ID: 15071260
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Stellbrink C; Hanrath P; Nixdorff U; Hofmann T; Lehmacher W; Kühle K; Fetsch T; Grewe R; Schmidt-Lucke JA;
Z Kardiol; 2002 Mar; 91(3):249-54. PubMed ID: 12001541
[TBL] [Abstract][Full Text] [Related]
4. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Schmidt-Lucke C; Paar WD; Stellbrink C; Nixdorff U; Hofmann T; Meurer J; Grewe R; Daniel WG; Hanrath P; Mügge A; Klein HU; Schmidt-Lucke JA
Thromb Res; 2007; 119(1):27-34. PubMed ID: 16443257
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.
Schädlich PK; Schmidt-Lucke C; Huppertz E; Lehmacher W; Nixdorff U; Stellbrink C; Brecht JG
Am J Cardiovasc Drugs; 2007; 7(3):199-217. PubMed ID: 17610347
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
[TBL] [Abstract][Full Text] [Related]
7. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study).
Sorino M; Colonna P; De Luca L; Carerj S; Oliva E; De Tommasi SM; Conti U; Iacopi F; D'Agostino C; D'Amato N; Pettinati G; Montericcio V; Cualbu A; De Luca I
J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1034-42. PubMed ID: 18163016
[TBL] [Abstract][Full Text] [Related]
8. Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.
Elliott DJ; Zhao L; Jasper SE; Lieber EA; Klein AL; Weintraub WS
Am Heart J; 2008 Aug; 156(2):374.e1-6. PubMed ID: 18657673
[TBL] [Abstract][Full Text] [Related]
9. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
Tebbe U
Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
[No Abstract] [Full Text] [Related]
10. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study.
Klein AL; Jasper SE; Katz WE; Malouf JF; Pape LA; Stoddard MF; Apperson-Hansen C; Lieber EA;
Eur Heart J; 2006 Dec; 27(23):2858-65. PubMed ID: 17098762
[TBL] [Abstract][Full Text] [Related]
11. [Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].
Schimpf T; Stellbrink C
Med Klin (Munich); 2003 Feb; 98(2):91-5. PubMed ID: 12601533
[TBL] [Abstract][Full Text] [Related]
12. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study.
Murray RD; Shah A; Jasper SE; Goodman A; Deitcher SR; Katz WE; Malouf JF; Stoddard MF; Grimm RA; Klein AL;
Am Heart J; 2000 Jun; 139(6):E1-7. PubMed ID: 10827367
[TBL] [Abstract][Full Text] [Related]
13. [Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Klein HH
Dtsch Med Wochenschr; 2013 Jun; 138(24):1309-11. PubMed ID: 23737116
[TBL] [Abstract][Full Text] [Related]
14. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
[TBL] [Abstract][Full Text] [Related]
15. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
16. Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).
Zhao L; Zhang Z; Kolm P; Jasper S; Lewis C; Klein A; Weintraub W;
Am J Cardiol; 2008 Feb; 101(3):338-42. PubMed ID: 18237596
[TBL] [Abstract][Full Text] [Related]
17. [Stroke with leg paralysis -- cardioversion in atrial fibrillation: prevention of thromboembolism in risk patients].
MMW Fortschr Med; 2006 Jun; 148(23):58-9. PubMed ID: 16826742
[No Abstract] [Full Text] [Related]
18. Anticoagulation with low-molecular-weight heparin in patients with heart diseases.
Bechtold H; Janssen D
Eur J Med Res; 2004 Apr; 9(4):186-98. PubMed ID: 15210399
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. Transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation: ACUTE trial update.
Asher CR; Klein AL;
Card Electrophysiol Rev; 2003 Dec; 7(4):387-91. PubMed ID: 15071261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
